Section Arrow
ADTX.NASDAQ
- Aditxt
Quotes are at least 15-min delayed:2024/05/16 08:19 EDT
Last
 2.05
-0.15 (-6.82%)
Day High 
2.225 
Prev. Close
2.2 
1-M High
3.08 
Volume 
24.55K 
Bid
2.14
Ask
2.22
Day Low
1.97 
Open
2.18 
1-M Low
1.95 
Market Cap 
3.66M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.19 
20-SMA 2.28 
50-SMA 2.87 
52-W High 68.08 
52-W Low 1.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-108.15/-91.97
Enterprise Value
4.71M
Balance Sheet
Book Value Per Share
9.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
645.18K
Operating Revenue Per Share
0.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 08:19 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.